


## BIOGRAPHICAL SKETCH (22.2.2018)

NAME Visakorpi, Tapio	
POSITION TITLE Dean, Faculty of Medicine and Life Sciences Professor of Cancer Genetics	

EDUCATION/TRAINING	INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
	University of Tampere, Tampere, Finland	M.D.	1990	
	University of Tampere, Tampere, Finland	Ph.D.	1992	cancer biology
	University of Tampere, Tampere, Finland	post-doc	1992-94	cancer genetics
	NHGRI (NCHGR)/NIH, Bethesda, MD, USA	post-doc	1994-96	cancer genetics

### Mission statement

I have worked on the molecular mechanisms of prostate cancer for more than 25 years. The main emphasis of my group has been in the identification of genomic alteration in prostate cancer by utilizing genome-wide tools such as arrays and next generation sequencing. A special area of the research has been the androgen receptor (AR) signaling in castration-resistant prostate cancer, especially the significance of the amplification of the AR gene. We have also been active in discovering and validating new biomarkers. In this respect, the focus has lately been in proteomic profiling and in liquid biopsies.

### Selected Other Current Professional Experiences

A member of the Scientific Counsel, Finnish Cancer Institute  
A board member, the Finnish Cancer Foundation  
Chairman of the Board, Biocenter Finland

### Honors

1997 The Outstanding Young Person, Junior Chamber Finland  
1999 The Young Researcher Award, The Finnish Medical Society Duodecim  
2007- Member of the Finnish Academy of Science and Letters  
2011 4th Dominique Chopin Distinguished Researcher Award, EAU Section of Urological Research

### Selected Publications (total n=212)

**Visakorpi T**, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi O-P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. *Nat Genet*, 9:401-406, 1995.

Liu W<sup>1</sup>, Laitinen S<sup>1</sup>, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, Nelson WG, Yegnasubramanian S, Luo J, Wang Y, Xu J, Isaacs WB, **Visakorpi T**, Bova GS. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. *Nat Med*, 15:559-565. 2009. <sup>1</sup>shared first authors.

Urbanucci A, Sahu B, Seppälä J, Larjo A, Latonen LM, Waltering KK, Tammela TLJ, Vessella RL, Lähdesmäki H, Jänne OA, **Visakorpi T**. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin. *Oncogene*, 31:2153–2163, 2012.

Gundem G, Van Loo P, Kremeyer B, Alexandrov L, Tubio J, Papaemmanuil E, Brewer D, Kallio H, Högnäs G, Annala M, Goody V, Latimer C, O'Meara S, Dawson K, Isaacs W, Emmert-Buck M, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker H, Neal D, Cooper C, Eeles R, **Visakorpi T**, Campbell P, McDermott U<sup>1</sup>, Wedge D<sup>1</sup>, Bova GS<sup>1</sup>. The evolutionary history of lethal metastatic prostate cancer. *Nature* 520:353-357, 2015. <sup>1</sup>shared correspondence.

Latonen L, Afyounian E, Jylhä A, Näntinen J, Aapola U, Annala M, Kivinummi KK, Tammela TLJ, Beuerman RW, Uusitalo H, Nykter M<sup>1</sup>, **Visakorpi T**<sup>1</sup>. Integrative analysis of the proteome in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. *Nat Comm*, accepted for publication, 2018. <sup>1</sup>shared correspondence.